Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

VANCOUVER, and SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three months ended July 31, 2007 and an update on its programs.

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. This confirmatory Phase III trial is a randomized, Evaluation Committee-blinded study to assess the effectiveness of Omigard(TM) vs. 10% povidone-iodine for the prevention of central venous catheter-related infections. This ongoing trial is known as the Central Line Infection Reduction Study, or CLIRS trial.

On July 30, 2007 Cadence Pharmaceuticals, our North American and European development and commercialization partner for Omigard(TM), announced that the FDA had agreed with their plan to increase the number of patients to be enrolled in CLIRS trial from 1,250 to 1,850. Cadence also announced that in June 2007 it completed enrollment of the original target of 1,250 patients in this clinical trial. Cadence expects they will complete enrollment of the new goal of 1,850 patients in the second quarter of 2008. If the results of the CLIRS trial are positive, Cadence expects to submit an NDA for omiganan 1% gel in the first half of 2009.

Celgosivir (MX-3253; oral a-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): Final top-line results of a Phase II combination study in non-responder and partial responder patients were announced April 11, 2007, demonstrating proof-of-concept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegylated interferon plus ribavirin) as compared to the active control treatment (standard-of-care
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... worldwide conservation efforts have made great strides in saving ... China, there are over 65 giant panda reserves that ... despite these efforts, just 1596 pandas remain in the ... zoos hope to save the panda by improving genetic ... the wild. Just how are these high-profile programs doing ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Shimadzu ... LC/MS amino acid analysis system developed jointly with ... UF-Amino Station can analyze 38 amino acids in ... UF-Amino Station achieves high-speed analysis utilizing a fast ... LCMS-2020 provides accurate analytical results even under conditions ...
(Date:7/23/2014)... TEL AVIV, Israel , July 23, 2014 ... Ltd ., a portfolio company of Trendlines ... with one of Israel,s ... (Logo: http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines ... from plant pulp waste, with additional nanoparticles to ...
(Date:7/23/2014)... July 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a ... is filing for two medical marijuana dispensary locations in ... addition to the Clark County, Nevada ... permit, as previously announced.  GrowBLOX Sciences, CEO ... two new applications for dispensaries in the City ...
Breaking Biology Technology:Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3
... Calif., March 20, 2012 Cepheid (NASDAQ: ... of Medicine and Dentistry of New Jersey (UMDNJ), it ... Health to develop sample processing and amplification methods for ... reaction (PCR) on the GeneXpert® System. The $1.3 million ...
... March 20, 2012 Heptares Therapeutics, the ... company of Shire PLC (LSE: SHP, NASDAQ: ... its exclusive option to license a novel adenosine A ... in preclinical development. Adenosine A 2A is a ...
... 19, 2012  MiMedx Group, Inc. (OTCBB: MDXG), an ... regenerative biomaterials and bioimplants processed from human amniotic ... distribution agreement with Systagenix, whereby Systagenix will co-market ... specifically processed from amniotic tissue, EpiFix® offers a ...
Cached Biology Technology:Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 2Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 3Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 4Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 2Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 3MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 2MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 3
(Date:7/23/2014)... strength, but it also holds the promise of a ... to convert sunlight into a clean, efficient alternative fuel. ... group using spinach to study the proteins involved in ... energy into carbohydrates used to power cellular processes. , ... efficient system ever built, capable of converting the energy ...
(Date:7/23/2014)... Migratory songbirds are disappearing, and though conservationists are examining ... habitat, acid rain and light pollution, a key piece ... birds go once they leave their breeding sites, and ... , To answer this question, a team of researchers ... migratory connectivity map produced for a songbird, using tracking ...
(Date:7/23/2014)... planet,s soil releases about 60 billion tons of carbon ... than that released by burning fossil fuels. This happens ... of carbon is balanced by carbon coming into the ... as well as by the underground activities of plant ... rising temperatures increase the rate of soil respiration. As ...
Breaking Biology News(10 mins):Spinach could lead to alternative energy more powerful than Popeye 2York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2Climate change and the soil 2
... 2012) Aeras and the Infectious Disease Research Institute ... trial of IDRI,s novel tuberculosis vaccine candidate, ID93 + ... safety, tolerability and immunogenicity of the vaccine candidate in ... by Johnson County Clin-Trials in Lenexa, Kansas, in close ...
... has on pregnancy, are urging men to get ... development. Reproductive experts from the University of ... father,s obesity negatively impacts sperm, resulting in smaller ... While the health risks surrounding obesity ...
... Venture has developed a framework to evaluate the risk ... A paper based on this work: A framework for ... has been published in the Malaria Journal ... anti-infective drug, so it is important when developing new ...
Cached Biology News:As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing 2Thinking about kids? Man, you gotta shed the kilos 2MMV develops framework to assess risk of resistance for antimalarial compounds 2